Lv11
30 积分 2024-01-25 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
4小时前
待确认
FDA-approved therapies for chronic GVHD
14天前
已完结
Discovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists
14天前
已完结
Chronic spontaneous urticaria: clinical features, diagnosis and management
26天前
已完结
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial
27天前
已完结
Proximod as a potential therapy for rheumatoid arthritis
27天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
1个月前
已完结
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects
1个月前
已完结
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
2个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2个月前
已完结
皖公网安备34019202002308
